The genetic diversity of human immunodeficiency virus (HIV) is a major concern thought to impact on immunologic escape and eventual vaccine efficacy. Here, simple and rapid methods are described for the detection and estimation of genetic divergence between HIV strains on the basis of the observation that DNA heteroduplexes formed between related sequences have a reduced mobility in polyacrylamide gels proportional to their degree of divergence. Reliable phylogenetic subtypes were assigned for HIV-1 strains from around the world. Relationships between viruses were closest when derived from the same or epidemiologically linked individuals. When derived from epidemiologically unlinked individuals, the relationships between viruses in a given geographic region correlated with the length of time HIV-1 had been detected in the population and the number of strains initiating widespread infection. Heteroduplex mobility analysis thus provides a tool to expedite epidemiological investigations by assisting in the classification of HIV and is readily applicable to the screening and characterization of other infectious agents and cellular genes.
Chronic hepatitis B virus (HBV) infection is a major cause of liver disease. Only interferon-alpha and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy. However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors. Potent new antiviral compounds suitable for monotherapy or combination therapy are highly desired. We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity. These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.
The vast majority of the world population is infected with at least one member of the human herpesvirus family. Herpes simplex virus (HSV) infections are the cause of cold sores and genital herpes as well as life-threatening or sight-impairing disease mainly in immunocompromized patients, pregnant women and newborns. Since the milestone development in the late 1970s of acyclovir (Zovirax), a nucleosidic inhibitor of the herpes DNA polymerase, no new non-nucleosidic anti-herpes drugs have been introduced. Here we report new inhibitors of the HSV helicase-primase with potent in vitro anti-herpes activity, a novel mechanism of action, a low resistance rate and superior efficacy against HSV in animal models. BAY 57-1293 (N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide), a well-tolerated member of this class of compounds, significantly reduces time to healing, prevents rebound of disease after cessation of treatment and, most importantly, reduces frequency and severity of recurrent disease. Thus, this class of drugs has significant potential for the treatment of HSV disease in humans, including those resistant to current medications.
Our previous data indicate that the expression of the PLK gene which codes for a serine/threonine kinase is restricted to proliferating cells. In Northern blot experiments PLK mRNA expression was at the limit of detection in normal lung tissue but elevated in most samples of non-small cell lung cancer (NSCLC). A very low frequency of PLK transcripts was only found in bronchiolo-alveolar carcinomas. NSCLC patients whose tumors showed moderate PLK expression survived signi®cantly longer (5 year survival rate=51.8%) than those with high levels of PLK transcripts (24.2%, P=0.001). No statistically signi®cant correlation was found between PLK mRNA expression and age, sex, TNM status, histological type or degree of dierentiation. Interestingly, the prognosis of patients in postsurgical stages I and II was correlated with PLK expression (5 year survival rates in stage I: 69.1% (moderate PLK) ± 43.5% (high PLK), P=0.03 or in stage II: 51.9% (moderate PLK) ± 9.9% (high PLK), P=0.006). These results suggest that PLK mRNA expression provides a new independent prognostic indicator for patients with NSCLC.
We have Identified the nucleotide sequence of the cDNA encoding the human counterpart of the moue gene Plk (polo-like kinase). . Activated Ras mediates signal transmission from receptor tyrosine kinases to a cascade of serine/threonine kinases including c-Raf, MEK, MAP kinase, and RSK (9). Many observations suggest that MAP kinase and RSK, which are located in the cytoplasm and in the nucleus, directly influence gene expression by phosphorylation of transcription factors (10, 11). Very recently, a MEK kinase independent ofRaf-1 has been described (12). Still, many components of this mitogenic cascade, such as protein kinases and many of their interactions, remain to be discovered.We and others have cloned cDNAs of novel protein kinases by using degenerate oligonucleotide primers for the PCR amplification of reverse-transcribed mRNA (13)(14)(15)(16)(17). A principal attraction of this approach is that based on conserved motifs of the kinase domain it allows amplification of protein kinases which are expressed at very low frequency. Here, we describe the PCR-based identification of a gene coding for a protein kinase from embryonic tissue. The complete cDNA was subsequently isolated from a cDNA library based on RNA from a squamous-cell lung carcinoma. The cDNA encodes a protein which seems to be the human counterpart of a mouse protein referred to as Plk (polo-like kinase) and contains structural hallmarks of protein-serine/ threonine kinases.t We show that expression of human PLK mRNA is increased in proliferating tissues like human tumors, as well as in cell lines and growth-stimulated primary cells. In quiescent cells, PLK transcripts were not found. These data suggest that PLK mRNA expression is tightly linked to proliferation.
A novel class of antibiotic acyldepsipeptides (designated ADEPs) exerts its unique antibacterial activity by targeting the peptidase caseinolytic protease P (ClpP). ClpP forms proteolytic complexes with heat shock proteins (Hsp100) that select and process substrate proteins for ClpP-mediated degradation. Here, we analyse the molecular mechanism of ADEP action and demonstrate that ADEPs abrogate ClpP interaction with cooperating Hsp100 adenosine triphosphatases (ATPases). Consequently, ADEP treated bacteria are affected in ClpP-dependent general and regulatory proteolysis. At the same time, ADEPs also activate ClpP by converting it from a tightly regulated peptidase, which can only degrade short peptides, into a proteolytic machinery that recognizes and degrades unfolded polypeptides. In vivo nascent polypeptide chains represent the putative primary target of ADEP-activated ClpP, providing a rationale for the antibacterial activity of the ADEPs. Thus, ADEPs cause a complete functional reprogramming of the Clp–protease complex.
Eph-related receptor tyrosine kinases (RTKs) have been implicated in intercellular communication during embryonic development. To elucidate their signal transduction pathways, we applied the yeast two-hybrid system. We could demonstrate that the carboxyl termini of the Eph-related RTKs EphA7, EphB2, EphB3, EphB5, and EphB6 interact with the PDZ domain of the ras-binding protein AF6. A mutational analysis revealed that six C-terminal residues of the receptors are involved in binding to the PDZ domain of AF6 in a sequencespecific fashion. Moreover, this PDZ domain also interacts with C-terminal sequences derived from other transmembrane receptors such as neurexins and the Notch ligand Jagged. In contrast to the association of EphB3 to the PDZ domain of AF6, the interaction with full-length AF6 clearly depends on the kinase activity of EphB3, suggesting a regulated mechanism for the PDZ-domain-mediated interaction. These data gave rise to the idea that the binding of AF6 to EphB3 occurs in a cooperative fashion because of synergistic effects involving different epitopes of both proteins. Moreover, in NIH 3T3 and NG108 cells endogenous AF6 is phosphorylated specifically by EphB3 and EphB2 in a ligand-dependent fashion. Our observations add the PDZ domain to the group of conserved protein modules such as Src-homology-2 (SH2) and phosphotyrosine-binding (PTB) domains that regulate signal transduction through their ability to mediate the interaction with RTKs.The effects of many growth factors and cytokines are mediated by high-affinity binding to receptor tyrosine kinases (RTKs) resulting in autophosphorylation of the cytoplasmic domain (1). Phosphotyrosine residues serve as binding sites for downstream signaling proteins that establish a complex network of interactions within the cell. Modular structures involved in binding of activated RTKs identified so far include Src-homology-2 (SH2) and phosphotyrosine-binding (PTB) domains, which both bind specifically to phosphorylated tyrosine residues in a sequencespecific fashion (2).Recently, we isolated two Eph-related RTKs, named EphB3 and EphB2 (refs. 3 and 4; B.B., U.H., T.K., and K.S., unpublished data), which both bind specifically to the transmembrane subgroup of Eph-receptor ligands (5, 6). The genetic analysis of EphB2 and EphB3 revealed a physiological requirement of both receptors for pathfinding of specific commissural axons in the central nervous system (7,8). To date, the information about signaling molecules mediating Eph-receptor-specific responses is still limited to a few family members. Interactions have been described for the activated Eph-family members EphA2, EphA4, and EphB1 and the SH2-domain-containing proteins p85 subunit of phosphatidylinositol 3-kinase, the adapter protein SLAP, Grb2, Grb10, and Fyn (8-11). Lately, we found that activated EphB3 interacts with Crk, Fyn, and rasGAP in a SH2-dependent manner (12): Autophosphorylation of Tyr-614 in the juxtamembrane region of the receptor generates a multi-docking-site for these interactions...
Cells containing reporters which are specifically induced via selected promoters are used in pharmaceutical drug discovery and in environmental biology. They are used in screening for novel drug candidates and in the detection of bioactive compounds in environmental samples. In this study, we generated and validated a set of five Bacillus subtilis promoters fused to the firefly luciferase reporter gene suitable for cell-based screening, enabling the as yet most-comprehensive high-throughput diagnosis of antibiotic interference in the major biosynthetic pathways of bacteria: the biosynthesis of DNA by the yorB promoter, of RNA by the yvgS promoter, of proteins by the yheI promoter, of the cell wall by the ypuA promoter, and of fatty acids by the fabHB promoter. The reporter cells mainly represent novel antibiotic biosensors compatible with high-throughput screening. We validated the strains by developing screens with a set of 14,000 pure natural products, representing a source of highly diverse chemical entities, many of them with antibiotic activity (6% with anti-Bacillus subtilis activity of <25 g/ml]). Our screening approach is exemplified by the discovery of classical and novel DNA synthesis and translation inhibitors. For instance, we show that the mechanistically underexplored antibiotic ferrimycin A1 selectively inhibits protein biosynthesis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.